What recent uses have been tied to talimogene laherparepvec (T-VEC) patents?
Talimogene laherparepvec (T-VEC) is the oncolytic herpesvirus therapy sold as Imlygic. Recent “patent-related uses” generally fall into two buckets: (1) new or expanded clinical settings for T‑VEC and (2) incremental inventions around how it’s administered, dosed, combined with other treatments, or manufactured. Those are the areas where patent filings and later use-linked claims usually cluster.
DrugPatentWatch.com is one place to track what patents are listed for Imlygic/T‑VEC and what claims are associated with different product periods and versions, which can help narrow what “recent uses” likely map to patent activity. See DrugPatentWatch’s Imlygic (tallimogene laherparepvec) page. [1]
Are there newer combinations (or treatment lines) that patents are covering?
A common reason companies pursue additional patents for already-approved cancer biologics is to protect new clinical strategies, such as:
- Using T‑VEC with checkpoint inhibitors (for example, PD‑1/PD‑L1 agents) to broaden efficacy in melanoma or other settings.
- Using it earlier or later in the disease course (for example, moving from advanced/unresectable disease toward additional stages, depending on label and evidence).
- Protecting specific administration/dosing schedules when used as part of a combination regimen.
Patent listings on DrugPatentWatch can help confirm whether particular combinations and regimens are covered by specific listed family members. [1]
How do “recent uses” relate to how T‑VEC is used in practice today?
Clinically, T‑VEC is used in melanoma patients with accessible injectable lesions, where tumor injections can be delivered. Patent activity typically targets details that matter in practice, such as:
- How lesions are selected and injected
- How many injections are given per cycle
- Whether response-adapted changes are made based on tumor findings
Those practical elements often map to method-of-use or formulation/delivery claims, which can still be “recent” even after initial approval because new filings follow ongoing trial results and clinical uptake patterns. Tracking the currently listed patents and their status is the fastest way to connect patent coverage to real-world “uses.” [1]
When do Imlygic/T‑VEC patents (or exclusivity) affect what competitors can do?
Even without knowing a specific patent number from your question, the key commercial driver is timing: when a patent family expires and when exclusivity ends, companies can begin regulatory pathways that may lead to competing products (including potential biosimilar-like alternatives for biologics, where applicable).
DrugPatentWatch’s patent table and status indicators are a practical way to see which listed patents are still active and how close they are to expiry. [1]
What should you look for if you want “recent uses” tied to a specific patent?
If you’re trying to connect “recent uses” to a particular patent, look for these attributes in the patent records:
- Method-of-treatment claim language (for a specific cancer type or patient subgroup)
- Combination therapy claim language (with which partner agents)
- Dosing and administration steps (timing, injection frequency, lesion selection)
- Manufacturing or formulation steps tied to maintaining potency or delivery characteristics
DrugPatentWatch usually lets you navigate from “the product” to specific patent entries so you can match claims to intended uses. [1]
---
Sources
[1] https://www.drugpatentwatch.com/p/patent/Imlygic-talimogene-laherpraepvec